{"DataElement":{"publicId":"6345597","version":"1","preferredName":"Common Terminology Criteria for Adverse Events Central Nervous System Necrosis Therapy Administered Text","preferredDefinition":"Free text to specify the treatment given for an Adverse Event of Central Nervous System Necrosis.","longName":"CTC_AE_CNS_NCR_TPY_ADMR_TXT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6422834","version":"1","preferredName":"Common Terminology Criteria for Adverse Events Central Nervous System Necrotic Process Therapeutic Procedure Administered","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event._The part of the nervous system that consists of the brain, spinal cord, and meninges._A cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).","longName":"2480706v1.0:6422839v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6422839","version":"1","preferredName":"Central Nervous System Necrotic Process Therapeutic Procedure Administered","preferredDefinition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.:A cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:The act of having given something (e.g., a medication or test).","longName":"C12438:C16897:C49236:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Necrotic Process","conceptCode":"C16897","definition":"A cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74A8B7DA-593A-50D3-E053-F662850A6A82","latestVersionIndicator":"Yes","beginDate":"2018-08-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-30","modifiedBy":"ONEDATA","dateModified":"2018-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74A898D7-B25D-50E3-E053-F662850A5B85","latestVersionIndicator":"Yes","beginDate":"2018-08-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-30","modifiedBy":"MAESKEB","dateModified":"2019-10-21","changeDescription":"Created for COG ACNS1721 request. 8.30.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188877","version":"1","preferredName":"Therapy Administered Text","preferredDefinition":"the free-text field for therapy administered.","longName":"TX_ADM_TXT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184342","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"Text","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2103-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5B3E07D-8601-16BD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2018-06-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-05","modifiedBy":"CAMPBELB","dateModified":"2018-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Describe the intervention use","type":"Preferred Question Text","description":"Describe the intervention used to treat CNS Necrosis:","url":null,"context":"COG"},{"name":"COG CRF Text 10","type":"Alternate Question Text","description":"Describe the intervention used to treat CNS necrosis (if applicable):","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"701F094A-CF15-7130-E053-F662850A68C0","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2018-07-03","modifiedBy":"COOPERM","dateModified":"2018-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}